8-K: Tilray Brands Reports Record Q1 Revenue and Gross Profit

Tilray Brands announced record first-quarter fiscal 2027 revenue of $257.1 million, up 23% year-over-year, with gross margin expanding to 30%.

Summary

• Tilray Brands reported record first-quarter fiscal 2027 revenue of $257.1 million, a 23% increase year-over-year.
• Gross profit rose 35% to $77.5 million, with gross margin expanding by 300 basis points to 30%.
• International business saw significant growth, with EMEA revenue up 71%, driven by medical cannabis, beverage, and pharmaceutical distribution.
• The global beverage business generated $101.5 million in revenue, with a 41% gross margin, and BrewDog achieved profitability.
• Outstanding debt was reduced by $42 million fiscal year-to-date, and the company ended the quarter with a net cash position.
• The company reaffirmed its fiscal year 2027 Adjusted EBITDA guidance of $68 million to $75 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and margin expansion, though net loss and adjusted EBITDA show slight declines.

Positives

• Record first-quarter net revenue of $257.1 million, up 23% year-over-year.
• Gross profit increased 35% year-over-year to $77.5 million.
• Gross margin expanded to 30% from 27%.
• EMEA revenue increased 71%, led by medical cannabis, beverage, and pharmaceutical distribution.
• Global beverage business revenue reached $101.5 million with a 41% gross margin.
• BrewDog achieved profitability in Q1.
• Reduced outstanding debt by $42 million fiscal year-to-date.
• Ended Q1 with a net cash position, strengthening financial flexibility.

Negatives

• Net loss for the quarter was $40.0 million, compared to a net income of $1.5 million in the prior year period.
• Adjusted EBITDA was $9.2 million, a decrease from $10.2 million in the prior year period, impacted by global fuel surcharges.
• Cannabis net revenue decreased to $56.1 million from $64.5 million year-over-year.
• Wellness gross margin decreased to 29% from 32%.

Risks

• The company's ability to achieve long-term profitability.
• Potential impact of U.S. federal cannabis legalization or rescheduling.
• Fluctuations in foreign currency exchange rates.
• Litigation costs and other non-recurring items that may be incurred.

Future Outlook

The company reaffirms its fiscal year 2027 Adjusted EBITDA guidance of $68 million to $75 million, representing double-digit growth compared to fiscal year 2026. Financial results are expected to be more weighted toward the second half of the fiscal year.

Management Comments

• "Tilray's record first-quarter revenue and gross profit demonstrate the power of the diversified platform we have built and the momentum we are creating across cannabis, beverage, hospitality, wellness and pharmaceutical distribution."
• "We are no longer dependent on a single market or regulatory catalyst. We have multiple engines of growth, a scaled international footprint and the ability to convert scale into stronger margins, greater efficiency and sustainable, profitable growth."
• "Our global platform is translating into leadership positions across our core categories."
• "Tilray is building a category-defining global platform for the next generation of wellness, healthcare and consumer products, with the brands, infrastructure and scale to lead as these markets evolve."
• "The quarter's performance reflects Tilray's focus on building durable growth across multiple categories, strengthening profitability and maintaining a disciplined balance sheet while investing behind the long-term opportunities we believe will define the future of cannabis, beverage, wellness and healthcare."

Industry Context

StockSavvy.ai notes that Tilray Brands' diversified strategy across cannabis, beverage, and distribution segments is a key differentiator in a rapidly evolving global market. The growth in international markets, particularly EMEA, and the successful integration and profitability of the beverage segment (including BrewDog) highlight the company's ability to execute on its multi-category approach, which is becoming increasingly important as the cannabis industry matures and diversifies.

Comparison to Industry Standards

• Tilray Brands is positioned as the #4 craft brewer in the U.S. and #1 in the U.K., indicating strong performance within the competitive craft beer market.
• The company's EU-GMP certified cultivation footprint is noted as one of the largest globally, suggesting adherence to high production standards in the medical cannabis sector.
• The beverage segment's gross margin of 41% is robust and competitive within the broader beverage industry.
• The company's stated goal of achieving Adjusted EBITDA of $68 million to $75 million for FY2027 will be a key benchmark against its own historical performance and industry peers in the cannabis and diversified consumer goods sectors.

Legal Proceedings

• Litigation costs, net of recoveries, were $0.8 million for the three months ended August 31, 2026, a decrease from $1.0 million in the prior year period.

Stakeholder Impact

• Shareholders: Positive impact from record revenue and gross profit, margin expansion, and debt reduction, though offset by increased net loss and slightly lower Adjusted EBITDA.
• Creditors: Positive impact from $42 million debt reduction and ending the quarter with a net cash position, strengthening the balance sheet.
• Employees: Potential positive impact from BrewDog achieving profitability and overall company growth momentum.
• Suppliers: Continued business with strong revenue growth in beverage and distribution segments may indicate stable demand.

Next Steps

• Continue to convert global scale, disciplined execution, and category leadership into higher revenue, expanded gross profit, and continued momentum.
• Focus on accelerating innovation and staying closer to consumers in beverage and wellness segments.
• Leverage the partnership with Carlsberg for U.S. market expansion starting January 1, 2027.
• Invest behind strategic growth opportunities and maintain disciplined capital allocation.
• Achieve fiscal year 2027 Adjusted EBITDA guidance of $68 million to $75 million.

Key Dates

Recommendation

The report shows strong top-line growth and margin expansion, indicating operational improvements and successful diversification. However, the increase in net loss and slight decrease in Adjusted EBITDA, coupled with the ongoing challenges in the cannabis segment, warrant a cautious approach. The company's strategic positioning and debt reduction are positive, but continued execution and profitability improvements are key for a stronger outlook.

Keywords

Tilray Brands, cannabis, beverage, revenue, gross profit, Adjusted EBITDA, debt reduction, financial results